Breast Cancer Genomics
- Cancer PHGKB -
What's New
Last Posted: Mar 07, 2019
- Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.
Sin Margaret et al. AMIA ... Annual Symposium proceedings. AMIA Symposium 2018 2018970-978 - Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
Swellam Menha et al. Journal of cellular biochemistry 2019 Mar - CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.
Mayer Sophie E et al. Cancer causes & control : CCC 2019 Jan 30(1) 103-112 - Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey.
Turbitt Erin et al. Preventive medicine 2019 Feb 12312-19 - Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer.
Saleh Amany A et al. Molecular biology reports 2019 Mar - RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.
Mirjolet C et al. EBioMedicine 2019 Feb - "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Colas Chrystelle et al. Breast (Edinburgh, Scotland) 2019 Jan 4529-35 - Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer.
Willoughby Ava et al. Journal of personalized medicine 2019 Mar 9(1) - Hereditary Breast Cancer: What You Can and Can't Learn from Genetic Testing,
by Dr. Constance M Chen, PRWeb, March 4, 2019 - Response to Roberts et al. 2018: cohort ascertainment and methods of analysis impact the association between cancer and genetic predisposition - the tale of breast cancer risk and Lynch syndrome genes MSH6/PMS2.
Wang Xia et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Feb - [Applying decision trees to establish risk rating model of breast cancer incidence based on non-genetic factors among Southwest China females].
Li Q et al. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2018 Nov 40(11) 872-877 - Clinical criteria revision for hereditary lobular breast cancer associated with E-cadherin germline mutations.
Corso Giovanni et al. Personalized medicine 2018 15(3) 153-155 - CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
Damkier Per et al. Scientific reports 2017 7(1) 7727 - Genetic Modifiers of the Breast Tumor Microenvironment.
Flister Michael J et al. Trends in cancer 2018 4(6) 429-444 - Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer.
Li Jie et al. International journal of cancer 2018 143(9) 2150-2160
No hay comentarios:
Publicar un comentario